Repligen (NASDAQ:RGEN) Shares Gap Up – Should You Buy?

Repligen Co. (NASDAQ:RGEN) shares gapped up before the market opened on Tuesday . The stock had previously closed at $168.01, but opened at $176.29. Repligen shares last traded at $172.44, with a volume of 272,942 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. HC Wainwright dropped their price target on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Canaccord Genuity Group initiated coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average price target of $184.73.

Repligen Price Performance

The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day simple moving average of $153.24 and a two-hundred day simple moving average of $147.20.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the business earned $0.23 EPS. On average, sell-side analysts forecast that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Several large investors have recently bought and sold shares of the stock. Champlain Investment Partners LLC grew its position in shares of Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in Repligen by 0.7% during the 4th quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company’s stock worth $136,395,000 after acquiring an additional 6,872 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock valued at $95,037,000 after purchasing an additional 36,773 shares during the last quarter. DF Dent & Co. Inc. raised its holdings in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after purchasing an additional 139,615 shares in the last quarter. Finally, New York State Common Retirement Fund increased its holdings in shares of Repligen by 14.4% in the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after acquiring an additional 71,274 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.